Lonza Group (FRA:LO3) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LO3 Lonza Group Ltd FRA:LO3
81 GF Score
Price €632.40
GF Value €647.98
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Lonza Group Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:LO3
81GF Score
Lonza Group Ltd FRA:LO3
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lonza Group (FRA:LO3) Overvalued in 2026?

Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued. The current stock price of €632.40 is trading 2.4% below its estimated GF Value™ of €647.98. GuruFocus considers Lonza Group to be Fairly Valued.

Key valuation signals for FRA:LO3:

  • Dividends Received:
  • GF Value™: €647.98 vs. price of €632.40 (2.4% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the FRA:LO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lonza Group Business Description

Address Muenchensteinerstrasse 38, Basel, CHE, 4002
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
81GF Score

Get the complete analysis for FRA:LO3

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€632.40
Price
€647.98
GF Value